Profile
| Metric | Value |
|---|---|
| Full Name | Oculis Holding AG |
| Ticker | NASDAQ: OCS |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Switzerland |
| IPO | |
| Indexes | Not included |
| Website | oculis.com |
| Employees | 49 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $19.75 | |
| Price, 1D Change | -1.25% | |
| Market Cap | $1B | |
| - | ||
| PE Ratio | - | |
| Beta | 0.65 | |
| Revenue | $0 | |
| Revenue, 1Y Change | 0.00% | |
| EPS | -$2.41 | |
| EPS, 1Y Change | +27.07% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$2.41 | |
| EPS Estimate | -$1.81 | |
| EPS Est. Change | +25.05% | |
| Revenue | $0.00 | |
| Revenue Estimate | $837.97K | |
| Revenue Est. Change | - | |
| Current Price | $19.75 | |
| Price Target | - | - |
| Price Tgt. Change | - | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$3.72 | -$3.31 | +11.16% | |
| -$1.84 | -$2.41 | -31.01% | |
| -$1.81 | N/A | +25.05% | |
| -$1.82 | N/A | +24.31% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $910.00K | $0.00 | -100.00% | |
| $927.01K | $0.00 | -100.00% | |
| $837.97K | N/A | - | |
| $5.64M | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +11.90% | |
| Price, 3Y | +95.93% | |
| Market Cap, 1Y | +48.15% | |
| Market Cap, 3Y | +757.41% | |
| Revenue, 1Y | 0.00% | |
| Revenue, 3Y | 0.00% | |
| EPS, 1Y | +27.07% | |
| EPS, 3Y | -2,327.82% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $19.75 | |
| SMA 200 | $18.74 | |
| SMA 200 vs Price | -5.10% | |
| SMA 50 | $19.92 | |
| SMA 50 vs Price | +0.84% | |
| Beta | 0.65 | |
| ATR | $0.74 | |
| 14-Day RSI | 46.67 | |
| 10-Day Volatility | 55.56% | |
| 1-Year Volatility | 43.36% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$2.41 | |
| Gross Profit | -$461.00K | |
| - | ||
| Operating Profit | -$83.17M | |
| - | ||
| Net Income | -$97.40M | |
| - | ||
| EBITDA | -$96.45M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.02 | |
| Current Ratio | 2.37 | |
| Quick Ratio | 2.37 | |
| Interest Coverage | -133.49 | |
| - | ||
| Altman Z-Score | 8.08 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | 6.96 | |
| EV/EBITDA | -10.38 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $81.22M | |
| Cash & Equivalents | $30.67M | |
| Total Assets | $132.80M | |
| Current Assets | $116.10M | |
| Total Liabilities | $51.83M | |
| Current Liabilities | $48.96M | |
| Total Debt | $1.30M | |
| Short Term Debt | $348.60K | |
| Accounts Payable | $6.50M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $83.17M | |
| Operating Expenses | $83.17M | |
| Cost Of Goods Sold | $461.00K | |
| SG&A | $21.50M | |
| D&A | $461.30K | |
| Interest Expense | $726.00K | |
| Income Tax | -$181.80K |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$53.97M | |
| CFI | -$19.95M | |
| CFF | $61.39M | |
| Capex | $261.20K | |
| Free Cash Flow | -$54.23M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Stifel | → | |
| JP Morgan | ||
| LifeSci Capital | ||
| B of A Securities | → | |
| Needham | → | |
| HC Wainwright & Co. | → | |
| Chardan Capital | → | |
| Chardan Capital | → | |
| HC Wainwright & Co. | → | |
| Needham |
Analyst sentiment
Institutional ownership
Screeners with OCS
Data Sources & References
- OCS Official Website oculis.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1953530/000095017025037224/0000950170-25-037224-index.htm
- OCS Profile on Yahoo Finance finance.yahoo.com/quote/OCS
- OCS Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/ocs
FAQ
What is the ticker symbol for Oculis Holding AG?
The ticker symbol for Oculis Holding AG is NASDAQ:OCS
Does Oculis Holding AG pay dividends?
No, Oculis Holding AG does not pay dividends
What sector is Oculis Holding AG in?
Oculis Holding AG is in the Healthcare sector
What industry is Oculis Holding AG in?
Oculis Holding AG is in the Biotechnology industry
What country is Oculis Holding AG based in?
Oculis Holding AG is headquartered in Switzerland
When did Oculis Holding AG go public?
Oculis Holding AG initial public offering (IPO) was on May 18, 2021
Is Oculis Holding AG in the S&P 500?
No, Oculis Holding AG is not included in the S&P 500 index
Is Oculis Holding AG in the NASDAQ 100?
No, Oculis Holding AG is not included in the NASDAQ 100 index
Is Oculis Holding AG in the Dow Jones?
No, Oculis Holding AG is not included in the Dow Jones index
When was Oculis Holding AG last earnings report?
Oculis Holding AG's most recent earnings report was on November 10, 2025
When does Oculis Holding AG report earnings?
The next expected earnings date for Oculis Holding AG is March 3, 2026